Roche named among top three most sustainable healthcare companies in the Dow Jones Sustainability Indices
December 15 2023 - 12:15AM
Roche named among top three most sustainable healthcare companies
in the Dow Jones Sustainability Indices
Roche named among top three most sustainable healthcare
companies in the Dow Jones Sustainability Indices
- The ranking acknowledges Roche’s commitment to
sustainability as an integral part of its business
strategy
- Roche performed particularly well in innovation
management, access to healthcare, greenhouse gas emissions, water
management, resource efficiency and circularity, labour practice
indicators and human rights
- This marks the 15th
consecutive year that Roche has maintained its leading
ranking
Basel, 15 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) has
again been recognised as one of the most sustainable companies in
the Pharmaceuticals index of the Dow Jones Sustainability Indices
(DJSI). Roche ranked third, Chugai Pharmaceuticals, a member of the
Roche Group, ranked second.
“We are extremely proud that our deep commitment to
sustainability in all our business practices has been recognised
again,” said Roche CEO Thomas Schinecker. “It is a fantastic
achievement that Chugai and Roche came in second and third,
respectively. This double recognition reflects the innovation the
Roche Group brings to society, and our commitment to continually
embed sustainable practices in our strategy and culture.”
For the past 15 consecutive years, Roche has maintained its
leading ranking, which is based on an in-depth analysis of
economic, social and environmental performance. The DJSI family of
indices serves as a benchmark for investors who integrate
sustainability considerations into their portfolios.
Sustainability at RocheFor over 125 years,
sustainability has been an integral part of Roche’s business. Roche
follows a holistic approach to sustainability and integrates the
three dimensions of sustainability:
- Society: how we contribute to a better tomorrow for all
- Environment: how we minimise our impact on nature
- Economy: how we invest in medical
advances, create jobs and ensure livelihoods
Roche makes its biggest contribution to society by improving
healthcare provision. It does so by developing innovative
treatments across major disease areas and medical assays, digital
solutions and services helping people live healthier lives.
Roche is aware that this cannot be done alone. The key to
creating sustainable value and growth lies in partnering with
stakeholders and engaging in open, constructive dialogue. By doing
so, Roche generates value for society and achieves sustainable
economic growth for the company. We apply this approach to reducing
our overall environmental impacts across our business, well beyond
decarbonisation, setting long-term goals, measuring our
environmental impact and having an end-to-end focus on our
products.
Further information on our activities across sustainability
areas can be found here:www.roche.com/sustainability
About the Dow Jones Sustainability Indices
(DJSI)This global ranking is published annually by the
S&P Dow Jones Indices (S&P DJI) and measures the
performance of the world’s sustainability leaders. S&P DJI
invites publicly traded companies to participate. Companies are
selected for the indices according to a systematic Corporate
Sustainability Assessment. Only firms that lead their industries
based on this assessment are included in the indices. This is
determined by a comprehensive assessment of long-term economic,
environmental and social criteria that take account of general as
well as industry-specific sustainability trends.
About Roche Founded in 1896 in Basel,
Switzerland, as one of the first industrial manufacturers of
branded medicines, Roche has grown into the world’s largest
biotechnology company and the global leader in in-vitro
diagnostics. The company pursues scientific excellence to discover
and develop medicines and diagnostics for improving and saving the
lives of people around the world. We are a pioneer in personalised
healthcare and want to further transform how healthcare is
delivered to have an even greater impact. To provide the best care
for each person, we partner with many stakeholders and combine our
strengths in Diagnostics and Pharma with data insights from the
clinical practice.
In recognising our endeavour to pursue a long-term perspective
in all we do, Roche has been named one of the most sustainable
companies in the pharmaceuticals industry by the Dow Jones
Sustainability Indices for the fifteenth consecutive year. This
distinction also reflects our efforts to improve access to
healthcare together with local partners in every country we
work.
Genentech, in the United States, is a wholly owned member of the
Roche Group. Roche is the majority shareholder in Chugai
Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected
by law.Roche Global Media RelationsPhone: +41 61
688 8888 / e-mail: media.relations@roche.com
Hans Trees, PhDPhone: +41 79 407
72 58 |
Nathalie
AltermattPhone: +41 79 771 05 25 |
Simon
GoldsboroughPhone: +44 797 32 72 915 |
Karsten
KleinePhone: +41 79 461 86 83 |
Nina
MählitzPhone: +41 79 327 54 74 |
Kirti
PandeyPhone: +49 172 6367262 |
Dr. Rebekka
SchnellPhone: +41 79 205 27 03 |
Sileia
UrechPhone: +41 79 935 81 48 |
Roche Investor Relations
Dr. Bruno
Eschli Phone: +41 61 68-75284 e-mail:
bruno.eschli@roche.com |
Dr.
Sabine BorngräberPhone: +41 61 68-88027 e-mail:
sabine.borngraeber@roche.com |
Dr.
Birgit MasjostPhone: +41 61 68-84814e-mail:
birgit.masjost@roche.com |
Dr.
Gerard Tobin Phone: +41 61 68-72942 e-mail:
gerard.tobin@roche.com |
Investor Relations North America
Loren
KalmPhone: +1 650 225 3217 e-mail:
kalm.loren@gene.com |
Roche (LSE:0QQ6)
Historical Stock Chart
From Aug 2024 to Sep 2024
Roche (LSE:0QQ6)
Historical Stock Chart
From Sep 2023 to Sep 2024